Mirae Asset Global Investments Co. Ltd. Sells 1,892 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Mirae Asset Global Investments Co. Ltd. cut its position in shares of Hims & Hers Health, Inc. (NYSE:HIMSFree Report) by 0.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 287,946 shares of the company’s stock after selling 1,892 shares during the period. Mirae Asset Global Investments Co. Ltd. owned approximately 0.13% of Hims & Hers Health worth $4,455,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in HIMS. Diversify Advisory Services LLC purchased a new position in shares of Hims & Hers Health in the 1st quarter worth $701,000. Principal Financial Group Inc. grew its position in Hims & Hers Health by 17.9% in the first quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock worth $258,000 after acquiring an additional 2,525 shares in the last quarter. Cornerstone Investment Partners LLC bought a new stake in Hims & Hers Health during the first quarter worth approximately $161,000. First National Trust Co bought a new stake in Hims & Hers Health during the first quarter worth approximately $232,000. Finally, Summit Trail Advisors LLC raised its position in Hims & Hers Health by 187.5% during the first quarter. Summit Trail Advisors LLC now owns 270,784 shares of the company’s stock valued at $4,189,000 after purchasing an additional 176,612 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 2.3 %

HIMS opened at $20.21 on Thursday. The stock’s fifty day moving average is $18.92 and its two-hundred day moving average is $14.20. The company has a market capitalization of $4.34 billion, a P/E ratio of -2,020.50 and a beta of 1.08. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMSGet Free Report) last announced its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. During the same quarter last year, the firm posted ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on HIMS shares. Citigroup cut Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $16.00 to $20.00 in a report on Wednesday, May 22nd. Canaccord Genuity Group started coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective on the stock. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Jefferies Financial Group lifted their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 27th. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research report on Tuesday, May 7th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Get Our Latest Stock Report on Hims & Hers Health

Insider Transactions at Hims & Hers Health

In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $12.54, for a total transaction of $2,368,655.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $12.54, for a total transaction of $2,368,655.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Soleil Boughton sold 2,335 shares of Hims & Hers Health stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total value of $47,353.80. Following the completion of the transaction, the insider now owns 169,144 shares in the company, valued at approximately $3,430,240.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 974,371 shares of company stock valued at $18,407,531. Company insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

(Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Featured Stories

Institutional Ownership by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.